Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious diseases. Leveraging its proprietary INFECT platform, Imunon aims to enhance immune response mechanisms, facilitating effective tumor eradication. With a diversified pipeline of therapeutics across multiple clinical stages and strategic collaborations that bolster its operational expertise, Imunon is strategically positioned to revolutionize immunotherapy, offering the potential to significantly enhance treatment outcomes for patients while shaping the future of the biopharmaceutical landscape.
| Revenue (TTM) | 125,000 |
| Gross Profit (TTM) | -409,917 |
| EBITDA | $-14.55M |
| Operating Margin | 0.00% |
| Return on Equity | -429.70% |
| Return on Assets | -78.00% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.41 |
| Price-to-Book | 1.16 |
| Price-to-Sales (TTM) | 17.94 |
| EV/Revenue | 4.004 |
| EV/EBITDA | 0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $5.61M |
| Float | $5.24M |
| % Insiders | 6.94% |
| % Institutions | 5.70% |
Volatility is currently expanding
Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma
LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m.
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its IMNN-001 development program for women with newly diagnosed advanced ovarian cancer.
Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens
Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J.
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IMNN and any ticker you trade — then tracks every position and per-strategy win rate.
